These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32408327)

  • 1. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
    Sakaguchi K; Kosaka M; Yamazaki Y
    Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two Cases of Lung Stage ⅢSquamous Cell Carcinoma Treated with Carboplatin (CBDCA)plus Nab-Paclitaxel(Nab-PTX)].
    Yoshino Y; Miyagi J; Toume R; Naha Y; Uchihara T; Akamine M; Nakazato H; Kawakami M; Tomori T; Nagayoshi S; Nagamine S; Tomiyama T; Ohmine Y; Sasaki H; Ishikawa M; Maeshiro K
    Gan To Kagaku Ryoho; 2019 Jul; 46(7):1171-1173. PubMed ID: 31296824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
    Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
    Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
    Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
    [No Abstract]   [Full Text] [Related]  

  • 6. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
    Nakamichi S; Kubota K; Matsuyama K; Misumi T; Kozuki T; Sugawara S; Naoki K; Kobayashi N; Shukuya T; Shimokawa T; Ishihara M; Wakui H; Hosomi Y; Tanaka H; Saito H; Hosokawa S; Takiguchi Y; Kasai T; Nokihara H; Morita R; Aono H; Furuya N; Okamoto H
    Clin Lung Cancer; 2024 Jan; 25(1):85-90. PubMed ID: 37981477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
    Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
    J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
    Kunimasa K; Nakamura H; Nishino K; Nakatsuka SI; Kumagai T
    J Thorac Oncol; 2019 Oct; 14(10):e231-e233. PubMed ID: 31558236
    [No Abstract]   [Full Text] [Related]  

  • 12. Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
    Nakashima K; Akamatsu H; Murakami H; Niwa T; Iwamoto Y; Ozawa Y; Yokoyama T; Shoda H; Yamamoto N; Yoshioka H; Masuda K; Naito T; Mori K; Takahashi T
    Anticancer Res; 2019 Mar; 39(3):1463-1468. PubMed ID: 30842183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
    Miyanaga A; Asahina H; Watanabe S; Shukuya T; Tsubata Y; Hosomi Y; Sugawara S; Maemondo M; Okano T; Morita S; Matsuyama K; Kobayashi K; Seike M
    Clin Lung Cancer; 2023 Jun; 24(4):371-375. PubMed ID: 36849264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    Hanna NH; Schneider BJ; Temin S; Baker S; Brahmer J; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Singh N; Spigel DR; Stabler JO; Tashbar J; Masters G
    J Clin Oncol; 2020 May; 38(14):1608-1632. PubMed ID: 31990617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report.
    Terashima Y; Matsumoto M; Ozaki S; Nakagawa M; Nakagome S; Terasaki Y; Iida H; Mitsugi R; Kuramochi E; Okada N; Inoue T; Matsuki S; Kitagawa S; Fukuizumi A; Onda N; Takeuchi S; Miyanaga A; Kasahara K; Seike M
    Front Immunol; 2024; 15():1370972. PubMed ID: 39206190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy].
    Nakamura S; Horiuchi N; Katsura D; Shichijo K; Yoshida S; Harada E; Matsushita T; Oshima Y; Matsuzaki Y; Tamaki Y; Kimura S; Takeichi T; Fujimoto H; Masuda K; Iwasaka N; Shinomiya S
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):965-8. PubMed ID: 18633226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
    Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
    Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.